Journal article
National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy
Urologic oncology, Vol.38(8), pp.687.e13-687.e18
08/2020
DOI: 10.1016/j.urolonc.2020.03.014
PMID: 32305267
Abstract
•Clinical Stage IIA testis cancer with normal tumor markers has favorable prognosis.•Dual therapy (chemotherapy and surgery) increases treatment burden.•Nationally, dual therapy is common and not associated with change in survival.•Use of adjuvant chemotherapy was not linked to findings after surgery.•Decisions after initial nodal surgery are opportunity to decrease treatment burden.
For marker-negative clinical stage (CS) IIA nonseminomatous germ cell tumor (NSGCT), National Comprehensive Cancer Network and American Urological Association guidelines recommend either retroperitoneal lymph node dissection (RPLND) or induction chemotherapy. The goal is cure with one form of therapy. We evaluated national practice patterns in the management of CSIIA NSGCT and utilization of secondary therapies.
The National Cancer Data Base was used to identify 400 men diagnosed with marker negative CSIIA NSGCT between 2004 and 2014 treated with RPLND or chemotherapy. Trends in the utilization of initial and adjuvant treatment (chemotherapy only, RPLND only, RPLND with adjuvant chemotherapy, and postchemotherapy RPLND) were analyzed.
Of the 400 cases, 233 (58%) underwent induction chemotherapy with surveillance, 51 (20%) underwent RPLND with surveillance, 89 (22%) underwent RPLND followed by adjuvant chemotherapy, and 14 (4%) underwent induction chemotherapy followed by RPLND. Thirty percent of patients received dual therapy. After RPLND with pN1 staging, 43 (61%) underwent adjuvant chemotherapy. The pN0 rate after primary RPLND was 22%. Five year overall survival ranged from 95% to 100% based on initial treatment choice.
For marker negative CS IIA nonseminoma, dual, therapy, and treatment with chemotherapy is common. With low volume retroperitoneal disease resected at RPLND, adjuvant chemotherapy was frequently administered but has debatable therapeutic value. These data highlight opportunities to decrease treatment burden in patients with CS IIA nonseminoma.
Details
- Title: Subtitle
- National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy
- Creators
- Craig V. Labbate - University of ChicagoRyan P. Werntz - Prisma HealthLogan B. Galansky - University of ChicagoVignesh T. Packiam - Mayo ClinicScott E. Eggener - University of Chicago
- Resource Type
- Journal article
- Publication Details
- Urologic oncology, Vol.38(8), pp.687.e13-687.e18
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.urolonc.2020.03.014
- PMID
- 32305267
- ISSN
- 1078-1439
- eISSN
- 1873-2496
- Language
- English
- Date published
- 08/2020
- Academic Unit
- Urology
- Record Identifier
- 9984319985702771
Metrics
13 Record Views